CBDX (Curative Biosciences) Debt-to-Equity: -0.48 (As of Mar. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Curative Biosciences Debt-to-Equity?

Curative Biosciences CBDX Debt-to-Equity is -0.48 as of Mar. 2018.

Curative Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2018 was $0.34 Mil. Curative Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2018 was $0.00 Mil. Curative Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2018 was $-0.71 Mil. Curative Biosciences's debt to equity for the quarter that ended in Mar. 2018 was -0.48.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Curative Biosciences's Debt-to-Equity or its related term are showing as below:

CBDX's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.275
* Ranked among companies with meaningful Debt-to-Equity only.

Curative Biosciences  (OTCPK:CBDX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Curative Biosciences Debt-to-Equity Related Terms

Curative Biosciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Curative Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biosciences Debt-to-Equity Chart

Curative Biosciences Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.08 -0.10

Curative Biosciences Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.10 0.00 0.00 -0.48

CBDX vs ACUR, CVLB, RDGL: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Curative Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biosciences Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curative Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Curative Biosciences's Debt-to-Equity falls into.


Curative Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Curative Biosciences's Debt to Equity Ratio for the fiscal year that ended in Jun. 2017 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.063 + 0) / -0.631
=-0.10

Curative Biosciences's Debt to Equity Ratio for the quarter that ended in Mar. 2018 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.338 + 0) / -0.706
=-0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.48 mean?
Curative Biosciences (CBDX) has a Debt-to-Equity of -0.48 as of Mar. 2018. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Curative Biosciences and its competitors.
Is Curative Biosciences' Debt-to-Equity too high?
Curative Biosciences' current Debt-to-Equity is -0.48.
How does Curative Biosciences' Debt-to-Equity compare to ACUR and CVLB?
Curative Biosciences' Debt-to-Equity of -0.48 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Curative Biosciences and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curative Biosciences's current Debt-to-Equity is -0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biosciences stock overvalued right now?
Curative Biosciences (CBDX) has a current Debt-to-Equity of -0.48. The current Debt-to-Equity is -0.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Curative Biosciences (CBDX), the current Debt-to-Equity is -0.48 as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biosciences Business Description

Address 2 South Biscayne Boulevard, Suite 3760, Miami, FL, USA, 33131
Curative Biosciences Inc is a life sciences company focused on developing and commercializing novel therapeutics using hemp-derived CBD. Its products comprise of CBD softgels, Hemp oil, and Topicals.